Effectiveness and Tolerability of Fondaparinux vs Enoxaparin in a Population of Indian Patients with Symptomatic Deep Vein Thrombosis: A Retrospective Real-World Study

• DOI: 10.1007/s40801-021-00273-4
• Publication Date: 2021-08-25T18:05:38Z
• Authors: Pinjala Ramakrishna; P. C. Gupta; Paresh Pai; Kumud Rai; M. Rajkumar; Tapish Sahu; Mohammed Yunus Khan; Kumar Gaurav; Amey Mane; Sucheta Pandit; Madhur Jain; Anand Subramaniyan
• Keywords: Fondaparinux; Tolerability; Enoxaparin sodium

Fondaparinux is the first approved anticoagulant drug among factor Xa inhibitors, with proven effectiveness and safety in preventing deep vein thrombosis. However, limited data are available supporting benefit-risk profile of fondaparinux vs enoxaparin a real-world group Indian patients thrombosis.To compare tolerability symptomatic thrombosis long-term setting.Data from electronic medical records adult diagnosed prescribed (n = 503) or 508) as monotherapy were analyzed. Effectiveness was analyzed terms recurrence, duration, type event, bleeding events at initial hospitalization follow-up visits up to 3 months duration. Appropriate statistical methods used determine significance (p < 0.05) between two groups.The recurrence non-inferior (2.78%) when compared (3.76%), mean duration 47 48 days, respectively. The number (in days) not significant > 0.05). Major higher 3.17% than 2.19%, difference statistically 0.05).The weight-based, once-daily subcutaneous dose showed comparable twice-daily for management